Perceptive Advisors LLC Disposes of Lyra Therapeutics Inc. Common Shares

Lyra Therapeutics Q3 EPS $(3.38) Beats $(5.25) Estimate, Sales $25.000K Miss $195.000K Estimate

Lyra Therapeutics Q3 net loss narrows

Lyra Therapeutics Inc Q3 Net Loss per Share $3.38

Perceptive Advisors LLC Reports Sale of Lyra Therapeutics Inc. Common Shares

Lyra Therapeutics Inc expected to post a loss of $5.25 a share - Earnings Preview

William Blair Keeps Their Hold Rating on Lyra Therapeutics (LYRA)

Lyra Therapeutics Inc - Enlighten 2 Trial Meets Primary Endpoint in Crs Symptoms

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

Lyra Therapeutics Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment

Lyra Therapeutics Receives Nasdaq Deficiency Notice for Failing to Meet Stockholders' Equity Requirement

U.S. RESEARCH ROUNDUP-ANI Pharmaceuticals, Berkshire Hathaway, Chevron

Lyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Lyra Therapeutics Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment

Lyra Therapeutics Inc - Financing Extends Cash Runway Into 3Q 2026

Lyra Therapeutics Inc expected to post a loss of $6.02 a share - Earnings Preview

Lyra Therapeutics Inc - Maria Palasis Appointed Chair of Lyra Board - SEC Filing

Lyra Therapeutics Inc - Terminates Executive Chairman Harlan Waksal - SEC Filing

Lyra Therapeutics Appoints Maria Palasis as Chair of the Board Following Departure of Executive Chairman Harlan Waksal

Lyra Therapeutics Inc. CFO Jason Cavalier Reports Disposal of Common Shares